CN1296087C - Compound capsule for treating apoplexy involving the meridians of wind phlegm stasis blockage syndrome type and preparation process thereof - Google Patents
Compound capsule for treating apoplexy involving the meridians of wind phlegm stasis blockage syndrome type and preparation process thereof Download PDFInfo
- Publication number
- CN1296087C CN1296087C CNB2004100839728A CN200410083972A CN1296087C CN 1296087 C CN1296087 C CN 1296087C CN B2004100839728 A CNB2004100839728 A CN B2004100839728A CN 200410083972 A CN200410083972 A CN 200410083972A CN 1296087 C CN1296087 C CN 1296087C
- Authority
- CN
- China
- Prior art keywords
- capsule
- radix
- filtrate
- group
- standby
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 206010062717 Increased upper airway secretion Diseases 0.000 title claims abstract description 15
- 208000026435 phlegm Diseases 0.000 title claims abstract description 15
- 150000001875 compounds Chemical class 0.000 title claims abstract description 13
- 208000006011 Stroke Diseases 0.000 title claims description 24
- 206010008190 Cerebrovascular accident Diseases 0.000 title claims description 23
- 208000011580 syndromic disease Diseases 0.000 title description 5
- 239000003814 drug Substances 0.000 claims abstract description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 35
- 239000008280 blood Substances 0.000 claims abstract description 25
- 210000004369 blood Anatomy 0.000 claims abstract description 25
- 239000000706 filtrate Substances 0.000 claims abstract description 18
- 239000000843 powder Substances 0.000 claims abstract description 15
- 238000010992 reflux Methods 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 8
- 230000002829 reductive effect Effects 0.000 claims abstract description 5
- 229940079593 drug Drugs 0.000 claims description 25
- 239000000796 flavoring agent Substances 0.000 claims description 12
- 235000019634 flavors Nutrition 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 241000237636 Pheretima Species 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 241000345998 Calamus manan Species 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 4
- 235000012950 rattan cane Nutrition 0.000 claims description 4
- 238000004064 recycling Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000002994 raw material Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 230000001154 acute effect Effects 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 7
- 206010008132 Cerebral thrombosis Diseases 0.000 abstract description 5
- 201000001429 Intracranial Thrombosis Diseases 0.000 abstract description 5
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 229940126678 chinese medicines Drugs 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 3
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 2
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 2
- 240000000031 Achyranthes bidentata Species 0.000 abstract 1
- 241000305491 Gastrodia elata Species 0.000 abstract 1
- 241000361919 Metaphire sieboldi Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 241001530038 Pantherophis obsoletus Species 0.000 abstract 1
- 206010041956 Stasis syndrome Diseases 0.000 abstract 1
- 241000157352 Uncaria Species 0.000 abstract 1
- 208000005634 blind loop syndrome Diseases 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 description 23
- 206010008118 cerebral infarction Diseases 0.000 description 17
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 16
- 201000006474 Brain Ischemia Diseases 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 206010008120 Cerebral ischaemia Diseases 0.000 description 13
- 210000004556 brain Anatomy 0.000 description 11
- 208000028867 ischemia Diseases 0.000 description 11
- 230000006378 damage Effects 0.000 description 10
- 230000003961 neuronal insult Effects 0.000 description 9
- 230000002792 vascular Effects 0.000 description 9
- 235000014655 lactic acid Nutrition 0.000 description 8
- 239000004310 lactic acid Substances 0.000 description 8
- 230000010412 perfusion Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 230000003727 cerebral blood flow Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 6
- 206010028851 Necrosis Diseases 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- 238000011049 filling Methods 0.000 description 5
- 210000001320 hippocampus Anatomy 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000017074 necrotic cell death Effects 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 206010004542 Bezoar Diseases 0.000 description 4
- -1 Calculus Bovis Awake Substances 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010048962 Brain oedema Diseases 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 3
- 102000004420 Creatine Kinase Human genes 0.000 description 3
- 108010042126 Creatine kinase Proteins 0.000 description 3
- 208000005189 Embolism Diseases 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 208000006752 brain edema Diseases 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 239000010225 buchang naoxintong Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000003710 cerebral cortex Anatomy 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 230000003118 histopathologic effect Effects 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 2
- 206010019468 Hemiplegia Diseases 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 206010039424 Salivary hypersecretion Diseases 0.000 description 2
- 208000008630 Sialorrhea Diseases 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 239000009335 naoxintong Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036581 peripheral resistance Effects 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241001312741 Gekko swinhonis Species 0.000 description 1
- 244000153234 Hibiscus abelmoschus Species 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000009519 fu-yuan Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000010273 nao xue shuan Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000009112 niuhuang Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 239000010356 tongguan Substances 0.000 description 1
- 239000008727 tongluo Substances 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000009692 xuesetong Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于中药技术领域，涉及一种用于治疗中风中经络风痰瘀阻的复方胶囊及其制备方法。本复方胶囊由胶囊及装入其中的由中药和辅料组成的粉状混合物；所述中药的成分为：天麻、赤芍、钩滕、地龙、豨莶草、川芎、丹参、乌梢蛇、炙远志和川牛膝。本复方胶囊的制备方法为：先将上述各味中药按要求炮制成饮片，取钩藤、丹参分别加乙醇回流提取二次，滤液浓缩至稠膏；取丹参醇提后药渣及其余的各味中药加水煎煮二次，滤液浓缩成稠膏状；将各稠膏合并，减压干燥，粉碎成细粉，加辅料混匀，装入胶囊，制得。本发明具有息风化痰，活血通络。用于风痰瘀阻证脑血栓之急性期及恢复早期者。它既保持了原有汤剂的特点，又具有起效快，服用方便等特点。The invention belongs to the technical field of traditional Chinese medicines, and relates to a compound capsule for treating wind-phlegm and blood stasis in meridians in stroke and a preparation method thereof. The compound capsule is composed of a capsule and a powdery mixture of traditional Chinese medicines and auxiliary materials packed therein; the ingredients of the traditional Chinese medicines are: gastrodia elata, red peony root, hook Teng, earthworm, siphonia, chuanxiong, salvia miltiorrhiza, black snake, Zhiyuanzhi and Sichuan Achyranthes bidentata. The preparation method of this compound capsule is as follows: first process the above-mentioned Chinese medicines into decoction pieces according to the requirements, take Uncaria uncariae and Salvia miltiorrhiza and add ethanol to reflux and extract twice, and the filtrate is concentrated to a thick paste; The traditional Chinese medicine is decocted twice with water, and the filtrate is concentrated into a thick paste; the thick pastes are combined, dried under reduced pressure, crushed into fine powder, mixed with auxiliary materials, and packed into capsules. The present invention has the functions of dispelling wind and reducing phlegm, promoting blood circulation and dredging collaterals. It is used in the acute stage and early recovery stage of cerebral thrombosis with wind-phlegm and blood stasis syndrome. It not only maintains the characteristics of the original decoction, but also has the characteristics of quick effect and convenient taking.
Description
Technical field
The invention belongs to technical field of Chinese medicines, particularly be used for the treatment of new drug of apoplexy and preparation method thereof.
Background technology
Apoplexy, promptly acute cerebrovascular disease is a kind of commonly encountered diseases of grievous injury human health.Along with the development of World Science technology and the raising of people's material life, rhythm of life is accelerated, and the variation of matter has taken place the human diseases spectrum.Since 20 centuries to the fifties, worldwide deadly infectious disease is controlled, and apoplexy, malignant tumor and coronary heart disease have become the three human big causes of death at present.
Apoplexy is divided into hemorrhagic apoplexy and cerebral infarction two classes by the reason and the character of its morbidity.The former comprises cerebral hemorrhage and subarachnoid hemorrhage; The latter comprises transient ischemic attack, cerebral thrombosis and cerebral infarction.Hemorrhagic apoplexy, doctor trained in Western medicine adopt operation and Drug therapy more, and curative effect is better than Chinese medicine.Cerebral infarction is that cerebral vessels is blocked suddenly, and the Therapeutic Principle alleviates cerebral edema, lowers blood viscosity, blood vessel dilating, anticoagulant and thrombolytic.Dialectical and the treatment of traditional Chinese medical science successive dynasties to cerebral infarction accumulated very rich experience and a large amount of effect sides medicine, and its etiology and pathogenesis has been formed the comparatively theory of system, still instructing the traditional Chinese medical science and the combination of Chinese and Western medicine to this sick clinical treatment so far effectively.Relevant in recent years this sick clinical research report is more, and also having developed some is the new Chinese medicine of indication with the apoplexy, but compares with the apoplexy sickness rate, mortality rate, the disability rate that raise day by day at present, and the new Chinese medicine of being developed still has the sense of deficiency.
The Chinese patent drugs for treatment of relevant cerebral thrombosis apoplexy apoplex involving the channels and collaterals.The general above-mentioned traditional ball powder preparation of respectively demonstrate,proving successive dynasties treatments " apoplexy " that adopts more.According to the retrieval, " national essential drugs Chinese medicine preparation kind catalogue " Chinese medicine preparation of recording cures mainly apoplexy person 36 kinds.Press syndrome-classification, windsyndrome caused by hyperactive liverYANG has An ' gong blood pressure-reducing ball, NAOLIQING WAN, clear dizzy paralysis treating medicine bolus, quick-acting cow-bezoar bolus; The obstruction of collateral caused by windphlegm card has ginseng restorative bolus, deep town wind ball, HUATUO ZAIZAO WAN, the urticaria of healing, fresh Succus Bambusae, Fufang Qianzheng cream, ginseng osmanthus restorative bolus; Expectorant heat-blockage resistance card has cow-bezoar bolus for resurrection, niuhuang zhibao pills, office side's most valuable treasure ball, bolus of cow-bezoar for clearing heart-fire, Succus Bambusae phlegm-resolving pill, Calculus Bovis Awake, tablet of cow-bezoar for tranquilization, TONGGUAN FEN; Syndrome of static blood blocking collaterals has embolism extinguishing oral liquid, PIANTAN FUYUAN WAN, DAHUOLUO WAN, HUOLUO WAN, ZHONGFENG HUICHUN WAN, XIAOSHUAN ZAIZAO WAN, xingnao zaizao pill, NIAOXUEKANG KOUFUYE, thromboembolism preventing to protect flourish capsule, XIAOSHUAN TONGLUO PIAN, XUESAITONG ZHUSHEYE, anti-embolism regenerative pill, Moschus antithrombotic pill, NAOXUESHUAN PIAN.
Take a broad view of these kinds, it is actually rare clearly to hinder the kind of compound pattern of syndrome with the apoplexy apoplex involving the channels and collaterals wind-phlegm stasis of blood, and the dosage form of above-mentioned this type of medicine mostly is pill, extremely is inconvenient to use, and does not also meet modern's medication psychology.
Summary of the invention
The objective of the invention is to propose a kind of compound capsule that is used for the treatment of the resistance of the apoplexy apoplex involving the channels and collaterals wind-phlegm stasis of blood and preparation method thereof, to satisfy the clinical needs of stroke patient for overcoming the weak point that the existing apoplexy apoplex involving the channels and collaterals wind-phlegm stasis of blood hinders compound pattern of syndrome medicine.
A kind of compound capsule that is used for the treatment of the resistance of the apoplexy apoplex involving the channels and collaterals wind-phlegm stasis of blood that the present invention proposes is characterized in that, by capsule and wherein the pulverulent mixture of being made up of Chinese medicine and adjuvant of packing into; The composition of described Chinese medicine and 1000 s' consumption is:
Rhizoma Gastrodiae 192-288g Radix Paeoniae Rubra 256-384g Ramulus Uncariae Cum Uncis 192-288g Pheretima 256-384g
Herba Siegesbeckiae 256-384g Rhizoma Chuanxiong 256-384g Radix Salviae Miltiorrhizae 256-384g Zaocys 192-288g
Cortex et Radix Polygalae (processed) 64-96g Radix Cyathulae 256-384g.
The preparation that the present invention proposes is used for the treatment of the method for the compound capsule of apoplexy apoplex involving the channels and collaterals wind-phlegm stasis of blood resistance, it is characterized in that, may further comprise the steps:
1) chooses Rhizoma Gastrodiae, Radix Paeoniae Rubra, Ramulus Uncariae Cum Uncis, Pheretima, Herba Siegesbeckiae, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Zaocys, Cortex et Radix Polygalae (processed) and Radix Cyathulae ten flavor Chinese crude drugs by 1000 recipe quantities and concoct into decoction pieces respectively on request;
2) hook taking rattan adds 4-6 and doubly measures 60-80% alcohol reflux secondary, and each 1-2 hour, merge extractive liquid, filtered, and filtrate is concentrated into the thick paste that relative density is 1.25～1.28 (60 ℃ of surveys), and is standby;
3) get Radix Salviae Miltiorrhizae, add 4-6 and doubly measure 60-90% alcohol reflux secondary, each 1-2 hour, merge extractive liquid, filtered, and medicinal residues are standby, and filtrate is concentrated into the thick paste that relative density is about 1.25～1.28 (60 ℃ of surveys), and is standby;
4) get medicinal residues and eight flavors such as remaining Rhizoma Gastrodiae, Radix Paeoniae Rubra, Pheretima, Herba Siegesbeckiae, Rhizoma Chuanxiong, Zaocys, Cortex et Radix Polygalae (processed) and Radix Cyathulae after the Radix Salviae Miltiorrhizae alcohol extraction, add 6-10 times of water gaging, decoct secondary, each 1-2 hour, collecting decoction filtered, filtrate is concentrated into relative density and is about 1.09～1.11 (60 ℃ of surveys), puts coldly, adds ethanol and makes the alcohol amount of containing be 50-70%, stir evenly, leave standstill more than 24 hours, filter filtrate recycling ethanol, it is standby to be condensed into thick paste shape (relative density is 1.25 ~ 1.28,60 ℃ of surveys);
5) above-mentioned standby thick paste is merged, drying under reduced pressure (control vacuum: 0.08MPa, temperature: 80 ℃) is ground into fine powder, adds starch or the about 40g of dextrin adjuvant, and mixing incapsulates, and makes.
Every of this product contains peoniflorin (C
23H
28O
11) be no less than 3.2mg.
Characteristics of the present invention and effect:
The present invention is capsule preparations (is called for short Gekko Swinhonis and goes on foot capsule again), and its content is tan powder; Feeble QI, the little acid and puckery of distinguishing the flavor of, little hardship.Have endogenous wind stopping and reduce phlegm, promoting blood circulation to remove obstruction in the collateral.Be used for the acute stage of wind-phlegm stasis of blood resistance card cerebral thrombosis (apoplexy apoplex involving the channels and collaterals) and recover early stage, disease is seen numb limbs and tense tendons, weak or hemiplegia, distortion of commissure, language sialorrhea person.
The used medical material of the present invention is recorded by version pharmacopeia in 2000.Crude drug source is extensive, and is cheap.Technical study has been determined best selection process (water decoction-alcohol sedimentation, alcohol extraction) by comparing the influence of Different Extraction Method to the curative effect of medication and the quality of the pharmaceutical preparations, with after pilot scale is amplified three batches, confirms that institute's selection process is reasonable, stable, but suitability for industrialized production.
Expermental research on main pharmacodynamics shows, this product is to cerebral thrombosis (apoplexy apoplex involving the channels and collaterals) acute stage and recover early stage, and disease sees that numb limbs and tense tendons, weak or hemiplegia, distortion of commissure, language sialorrhea person have obvious therapeutic action.
Acute toxicity test, long term toxicity test result show that the safety of this capsule is good, meet the drug safety principle.
According to situations such as the characteristics of physicochemical property, the clinical indication of the main effective ingredient of each flavour of a drug in the prescription and dosages, selecting the said preparation most preferred dosage form is capsule, and it had both kept the characteristics of original decoction, had characteristics such as rapid-action, taking convenience again.
The specific embodiment
Embodiment 1 is a capsule, and content is tan powder; Feeble QI, the little acid and puckery of distinguishing the flavor of, little hardship.By capsule and wherein the pulverulent mixture of forming by Chinese medicine and adjuvant of packing into; The composition of described Chinese medicine and 1000 s' consumption is:
Rhizoma Gastrodiae 288g Radix Paeoniae Rubra 384g Ramulus Uncariae Cum Uncis 288g Pheretima 384g
Herba Siegesbeckiae 384g Rhizoma Chuanxiong 384g Radix Salviae Miltiorrhizae 384g Zaocys 288g
Cortex et Radix Polygalae (processed) 96g Radix Cyathulae 384g.
Every of present embodiment contains peoniflorin (C
23H
28O
11) be no less than 3.2mg.
Every 4 of dress 0.4g one time is oral, 3 times on the one.
The preparation method of present embodiment may further comprise the steps:
1) chooses Rhizoma Gastrodiae, Radix Paeoniae Rubra, Ramulus Uncariae Cum Uncis, Pheretima, Herba Siegesbeckiae, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Zaocys, Cortex et Radix Polygalae (processed) and Radix Cyathulae ten flavor Chinese crude drugs by recipe quantity and concoct into decoction pieces respectively on request;
2) hook taking rattan adds 5 times of amount 70% alcohol reflux secondaries, and each 1 hour, merge extractive liquid, filtered, and filtrate is concentrated into the thick paste that relative density is about 1.25～1.28 (60 ℃ of surveys), and is standby;
3) get Radix Salviae Miltiorrhizae, add 5 times of amount 80% alcohol reflux secondaries, each 1 hour, merge extractive liquid, filtered, and medicinal residues are standby, and filtrate is concentrated into the thick paste that relative density is about 1.25～1.28 (60 ℃ of surveys), and is standby;
4) get eight flavors such as medicinal residues and residue Rhizoma Gastrodiae after the Radix Salviae Miltiorrhizae alcohol extraction, add 6 times of water gagings, decoct secondary, each 1 hour, collecting decoction filtered, filtrate is concentrated into relative density and is about 1.09～1.11 (60 ℃ of surveys), puts coldly, adds ethanol and makes that to contain alcohol amount be 70%, stir evenly, leave standstill more than 24 hours, filter filtrate recycling ethanol, it is standby to be condensed into thick paste shape (relative density is 1.25-1.28,60 ℃ of surveys);
5) above-mentioned standby thick paste is merged, drying under reduced pressure (control vacuum: 0.08MPa, temperature: 80 ℃) is ground into fine powder, adds the about 40g of starch, and mixing incapsulates, and makes 1000, promptly.
Embodiment 2 is a capsule, and content is tan powder; Feeble QI, the little acid and puckery of distinguishing the flavor of, little hardship.By capsule and wherein the pulverulent mixture of forming by Chinese medicine and adjuvant of packing into; The composition of described Chinese medicine and 1000 s' consumption is:
Rhizoma Gastrodiae 192g Radix Paeoniae Rubra 256g Ramulus Uncariae Cum Uncis 192g Pheretima 256g
Herba Siegesbeckiae 256g Rhizoma Chuanxiong 256g Radix Salviae Miltiorrhizae 256g Zaocys 192g
Cortex et Radix Polygalae (processed) 64g Radix Cyathulae 256g.
Every of present embodiment contains peoniflorin (C
23H
28O
11) be no less than 3.2mg.
Every 4 of dress 0.4g one time is oral, 3 times on the one.
The preparation method of present embodiment may further comprise the steps:
1) chooses Rhizoma Gastrodiae, Radix Paeoniae Rubra, Ramulus Uncariae Cum Uncis, Pheretima, Herba Siegesbeckiae, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Zaocys, Cortex et Radix Polygalae (processed) and Radix Cyathulae ten flavor Chinese crude drugs by recipe quantity and concoct into decoction pieces respectively on request;
2) hook taking rattan adds 6 times of amount 80% alcohol reflux secondaries, and each 2 hours, merge extractive liquid, filtered, and filtrate is concentrated into the thick paste that relative density is about 1.25～1.28 (60 ℃ of surveys), and is standby;
3) get Radix Salviae Miltiorrhizae, add 6 times of amount 90% alcohol reflux secondaries, each 2 hours, merge extractive liquid, filtered, and medicinal residues are standby, and filtrate is concentrated into the thick paste that relative density is about 1.25～1.28 (60 ℃ of surveys), and is standby;
4) get eight flavors such as medicinal residues and residue Rhizoma Gastrodiae after the Radix Salviae Miltiorrhizae alcohol extraction, add 10 times of water gagings, decoct secondary, each 2 hours, collecting decoction filtered, filtrate is concentrated into relative density and is about 1.09～1.11 (60 ℃ of surveys), puts coldly, adds ethanol and makes that to contain alcohol amount be 50%, stir evenly, leave standstill more than 24 hours, filter filtrate recycling ethanol, it is standby to be condensed into thick paste shape (relative density is 1.25-1.28,60 ℃ of surveys);
5) above-mentioned standby thick paste is merged, drying under reduced pressure (control vacuum: 0.08M Pa, temperature: 80 ℃) is ground into fine powder, adds the about 40g of dextrin, and mixing incapsulates, and makes 1000, promptly.
It is as follows that the present invention carries out the preliminarily stabilised test:
According to the specification requirement of Chinese medicine research, the method that adopts room temperature to keep sample is carried out study on the stability to three batches of these capsule samples.Promptly under the condition of " bottled ", with three batch samples, lot number is followed successively by: 040201,040202,040203, at room temperature placed 3 months, carry out every index examination respectively at 0 month, January, February, March, and with detected the result in 0 month and compare, the result shows that every index has no significant change, and shows that this capsule preliminarily stabilised is good.
The present invention is as follows to the result of the test of rat long term toxicity:
With content 6.88g/kg of the present invention, 3.44g/kg, 1.72g/kg (be equivalent to 47.04,23.52 respectively, the 11.76g crude drug/kg) three dosage are given rat oral gavage (ig), continuous 6 months, observe the general state situation of animal behind the medicine: outward appearance sign, behavioral activity, breathing, reach periodic logging body weight, food-intake, after administration 3 months, administration 6 months and drug withdrawal 15 days, respectively put to death 1/3 animal respectively, and carry out hematology, blood biochemical and cardinal principle, organ coefficient and histopathologic examination.The result, during the administration, each treated animal is not seen untoward reaction, body weight increment, food-intake, hematology and blood biochemical learn every index and matched group compares, difference that there are no significant, animal viscera reaches main organs histopathologic examination substantially except that the minority animal lung has blood stasis, chronic matter inflammation, and all the other also find that obviously unusual histopathology changes.
The capsular effect experiment of the present invention is as follows:
By three kinds of animals, the Multitest method has been carried out the pharmacology evaluation of cerebral ischemia aspect to this capsule, the result shows, this capsule can obviously reduce cerebral edema and cerebral tissue lactic acid content due to the acute cerebral ischemia in rats, compare with perfusion group again, the medication group has the effect of increasing the cerebral tissue creatine phosphokinase, and pathological examination proves, the ischemia-reperfusion neuronal damage obviously increases the weight of and administration group and positive drug group, has the effect that alleviates brain injury.Same this medicine is cerebral blood flow increasing amount and reduction cerebral vascular resistance and total peripheral resistance obviously, but blood pressure, heart rate there is not obvious influence, this product also can reduce whole blood contrast viscosity, plasma viscosity, packed cell volume and the platelet aggregation intensity of blood stasis model animal simultaneously, and suppressing thrombosis length and weight, this product also can prolong blood coagulation time and cerebral ischemia mice time-to-live in addition.
One, this capsule is to the influence of anesthetized dog cerebral blood flow and cerebral vascular resistance
The result shows: each group of this capsule administration and matched group all do not have obvious influence to the dog heart rate.Each group of administration and matched group all do not have obvious influence to dog systolic pressure, dog diastolic pressure, dog mean blood pressure.
Each group of this capsule administration and matched group all do not have obvious influence to dog left indoor pressure, left chamber end diastolic pressure.Each group of this capsule administration and matched group to the dog left indoor pressure maximum rise, fall off rate (± dp/dtmax) does not all have obviously and influences.
Change percentage rate after this capsule 0.65g powder/kg, 0.26g powder/kg and the administration of three dosage groups of 0.13g powder/kg at 45～180 minutes, compare, all can obviously increase the dog cerebral blood flow, have obvious statistical significance (p＜0.05, p＜0.01) with matched group.Change percentage rate after the positive drug BUCHANG NAOXINTONG JIAONANG 0.65g/kg administration at 45～180 minutes, have obvious cerebral blood flow increasing amount equally, (p＜0.05, p＜0.01).Each group of medication compares no significant difference with the positive drug group, and statistical procedures is meaningless.
Change percentage rate after this capsule 0.65g powder/kg group administration and can obviously reduce cerebral vascular resistance, relatively have obvious statistical significance (p＜0.01, p＜0.05) with matched group at 45～180 minutes.Changed percentage rate 45～120 minutes after this capsule 0.26g powder/kg group administration, can obviously reduce cerebral vascular resistance (p＜0.05), measured value was at 45～150 minutes, same obviously reduction cerebral vascular resistance (p＜0.05), change percentage rate at 45～120 minutes after this capsule 0.13g powder/kg group administration, obviously reduce cerebral vascular resistance (p＜0.05), change percentage rate after the NAOXINTONG JIAONANG 0.65g/kg administration, also can obviously reduce cerebral vascular resistance (p＜0.01, p＜0.05) at 45～180 minutes.
Two, this capsule is to the protective effect of cerebral ischemia
1) variation of brain water content
Ischemia group Mus brain water content is apparently higher than sham-operation line (P＜0.01); Perfusion group does not more relatively have significant difference (P＞0.05) with simple ischemia group.The large, medium and small dosage group of this capsule all significantly reduces (P＜0.05, P＜0.001, P＜0.01) than filling group again.Positive control drug group brain water content relatively has reduction trend, but statistics meaningless (P＞0.05) with perfusion again.
2) variation of cerebral tissue lactic acid content
Ischemia group murine brain lactic acid content increases (P＜0.001) than sham operated rats is remarkable, lactic acid further raises in the murine brain of filling group again, apparently higher than ischemia group (P＜0.001).This capsule for treating group murine brain lactic acid content all is starkly lower than ischemia group and perfusion group again (P＜0.001, P＜0.001, P＜0.001).Increase with this capsular dosage, lactic acid content reduces obviously in the cerebral tissue.The lactic acid content of positive control drug group also is starkly lower than perfusion group again (P＜0.001).
3) variation of cerebral tissue creatine phosphokinase (CPK)
In the sham operated rats rat cerebral tissue CPK content be 1410,2 ± 106.5u/g, CPK content obviously reduces in the simple ischemia group cerebral tissue, with sham operated rats comparing difference significantly (P＜0.001); Compare with ischemia group, CPK content further reduces (P＜0.001) in the cerebral tissue of filling group again.From this capsule for treating group as seen: the CPK content of large, medium and small three dosage groups all obviously raises, with the comparing difference of filling group more remarkable (P＜0.001).The CPK content of positive drug group also obviously raises, and relatively there were significant differences (P＜0.001) with perfusion group again.
4) brain CA1 and cortical areas's neure damage degree
Under optical microscope, each is organized tissue morphology and observes as follows:
A, simple cerebral ischemia group: the one-sided or obvious neuronal damage in bilateral Hippocampus CA1 district, the animal that has has neuronal necrosis widely from CA1 to CA4, and cortex mostly is neuronal necrosis.
B, sham operated rats: brain neuron injury is light, and individual animal visible Hippocampus CA1 district and cortical neuron have the sporadoneure damage.
C, cerebral ischemia re-pouring group: damage location is with simple cerebral ischemia group, but degree of injury is than obviously increasing the weight of.
D, positive control drug group: most of animal brain neuronal damages are lighter, the visible sporadoneure damage of individual animal Hippocampus CA1 and cortical areas.
E, low dose of investigational agent group: the half animal does not detect Hippocampus CA1 district neuron obvious necrosis, and the most of neurons of cortex are normal, and neuronal damage is arranged individually.
F, middle dosetest medicine group: most animals hippocampal neuron visible damage, the also visible more neuronal necrosis of cortex.
G, heavy dose of investigational agent group: the anatomical lesion degree is with middle dosetest medicine group.
Conclusion:
The success of operation cerebral ischemic model, brain neuron injury obviously increases the weight of behind the ischemia-reperfusion, positive controls has better prevention effect to the ischemic neuronal damage, little, in, heavy dose of investigational agent group all has preventive and therapeutic effect to the ischemic neuronal damage, and is but more obvious with the small dose group effect.
The histopathology brain tissue impairment, in this capsule of semiquantitative determination, relatively there were significant differences for low dose group and filling group again, illustrates that this capsule has the certain protection effect to cerebral tissue and neuron, but low dose of show more obvious.
Annotate: owing to adopt four duct ligation hypodesmus, it is downright bad that neuronal damage forms the zone, and necrocytosis is decentralized, so can't measure infarct size.Represent with semiquantitative determination.
Three, this capsule is to the influence of rat plasma platelet aggregation
The high, medium and low three kinds of dosage of this capsule all have in various degree inhibitory action to the rat plasma platelet aggregation, wherein the effect of 1.72g/kg group is the most obvious, effect is better than the positive reference substance BUCHANG NAOXINTONG, the maximum suppression ratio of assembling of medication group is respectively 24.82,15.03,13.28%, and BUCHANG NAOXINTONG is 16.96%.
Four, this capsule is to the influence of hemorheology of rat
This capsule in high dose group to the height of animal's whole blood specific viscosity cut, in cut, low cut, packed cell volume and plasma viscosity all have tangible reduction effect, illustrate that this product can obviously improve " viscosity " of body blood, " concentration ", thereby play the effect of invigorating blood circulation.
Five, this capsule is to the thrombotic influence of rats in vitro
This capsule in high dose group forms rats in vitro blood shape has the obvious suppression effect, though middle dosage group has inhibition trend to external thrombus, statistical procedures is meaningless, and positive drug NAOXINTONG inhibitory action is similar to high dose.
Six, this capsule is to the influence of clotting time of mice
This capsule height, middle dosage group have tangible prolongation effect to clotting time of mice.
Seven, this capsule is to the influence of mouse brain ischemia time-to-live
[3]
Adopt straightforward procedure to cause the death of mouse brain ischemia, this capsule in high dose group can prolong the mice time-to-live, compares P＜0.05 with matched group.
Every cerebral ischemia result of the test shows: three kinds of various dose of this capsule, can obviously reduce (four duct ligation hypodesmus) cerebral edema and cerebral tissue lactic acid content due to the acute cerebral ischemia in rats, have the effect of increasing the cerebral tissue creatine phosphokinase with the comparison of perfusion group again medication group, illustrate that this product can alleviate brain tissue impairment and the Physiology and biochemistry environment that improves brain.Histopathologic examination confirms; ischemia-reperfusion and simple ischemia group cerebral cortex district and Hippocampus CA1 district neuronal damage obviously increase the weight of; and administration group and positive reference substance neuronal damage are lighter; the necrosis region area reduces, and the effect that medicine has the excellent protection cerebral tissue and alleviates degree of injury is described.Same this medicine is obviously cerebral blood flow increasing amount, reduction cerebral vascular resistance and total peripheral resistance also, but blood pressure, heart rate are not had obvious influence, and the variation of these indexs is useful for anti-cerebral ischemia.Experiment has also been measured the platelet aggregation response curve by rat plasma, and the result shows that this medicine has the obvious suppression effect to platelet aggregation, the maximum suppression ratio of assembling, and the medication group is respectively 39.08,22.24,14.68%.The inside and outside thrombotest of body has illustrated that equally this medicine can obviously suppress thrombosis, points out it can obviously reduce thrombosis.Hemorheology index is measured and to be shown, to whole blood contrast viscosity, plasma viscosity, packed cell volume and significant reduction effect is all arranged.In addition, this product also can prolong blood clotting time and chmice acute cerebral ischemia time-to-live.These pharmacologically actives have confirmed the therapeutical effect of this capsule to cerebral ischemia.
In sum; various dose shown in this capsule has the certain protection effect to the brain tissue impairment that is caused by cerebral ischemia; but also cerebral blood flow increasing amount and reduction cerebral vascular resistance simultaneously; reduce platelet aggregation, reduce blood viscosity, the concentration of blood stasis model animal; restrain pharmacological actions such as thrombosis and prolongation clotting time; consistent with the clinical practice curative effect, illustrate that the present invention is the active drug of treatment apoplexy.
Claims (2)
1, a kind of compound capsule that is used for the treatment of apoplexy apoplex involving the channels and collaterals wind-phlegm stasis of blood resistance, this compound capsule is made up of the capsule and the pulverulent mixture of being made up of middle pharmaceutically active ingredient and adjuvant of packing into wherein; By preparation 1000 capsules, described Chinese medicine active ingredient raw materials is made up of the medicine of following consumption:
Rhizoma Gastrodiae 192-288g Radix Paeoniae Rubra 256-384g Ramulus Uncariae Cum Uncis 192-288g
Pheretima 256-384g Herba Siegesbeckiae 256-384g Rhizoma Chuanxiong 256-384g
Radix Salviae Miltiorrhizae 256-384g Zaocys 192-288g Cortex et Radix Polygalae (processed) 64-96g
Radix Cyathulae 256-384g.
2, according to the preparation method of the compound capsule that is used for the treatment of apoplexy apoplex involving the channels and collaterals wind-phlegm stasis of blood resistance of claim 1, it is characterized in that, may further comprise the steps:
1) chooses Rhizoma Gastrodiae, Radix Paeoniae Rubra, Ramulus Uncariae Cum Uncis, Pheretima, Herba Siegesbeckiae, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Zaocys, Cortex et Radix Polygalae (processed) and Radix Cyathulae ten flavor Chinese crude drugs and concoct into decoction pieces respectively on request;
2) hook taking rattan adds 4-6 and doubly measures 60-80% alcohol reflux secondary, and each 1-2 hour, merge extractive liquid, filtered, and it is 1.25～1.28 thick paste that filtrate is concentrated into relative density, standby;
3) get Radix Salviae Miltiorrhizae, add 4-6 and doubly measure 60-90% alcohol reflux secondary, each 1-2 hour, merge extractive liquid, filtered, and medicinal residues are standby, and filtrate is concentrated into relative density and is about 1.25～1.28 thick paste, and is standby;
4) get medicinal residues and eight flavors such as remaining Rhizoma Gastrodiae, Radix Paeoniae Rubra, Pheretima, Herba Siegesbeckiae, Rhizoma Chuanxiong, Zaocys, Cortex et Radix Polygalae (processed) and Radix Cyathulae after the Radix Salviae Miltiorrhizae alcohol extraction, add 6-10 times of water gaging, decoct secondary, each 1-2 hour, collecting decoction filtered, filtrate is concentrated into relative density and is about 1.09～1.11, put coldly, add ethanol and make the alcohol amount of containing be 50-70%, stir evenly, leave standstill more than 24 hours, filter, filtrate recycling ethanol, it is standby to be condensed into the thick paste shape;
5) above-mentioned standby thick paste is merged, drying under reduced pressure is ground into fine powder, adds starch or the about 40g of dextrin adjuvant, and mixing incapsulates, and makes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100839728A CN1296087C (en) | 2004-10-15 | 2004-10-15 | Compound capsule for treating apoplexy involving the meridians of wind phlegm stasis blockage syndrome type and preparation process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100839728A CN1296087C (en) | 2004-10-15 | 2004-10-15 | Compound capsule for treating apoplexy involving the meridians of wind phlegm stasis blockage syndrome type and preparation process thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1602949A CN1602949A (en) | 2005-04-06 |
| CN1296087C true CN1296087C (en) | 2007-01-24 |
Family
ID=34667021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100839728A Expired - Lifetime CN1296087C (en) | 2004-10-15 | 2004-10-15 | Compound capsule for treating apoplexy involving the meridians of wind phlegm stasis blockage syndrome type and preparation process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1296087C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857627B (en) * | 2006-04-12 | 2010-05-19 | 贵阳利多药物技术开发有限公司 | Apoplexy treating Chinese medicine preparation and its preparing process |
| CN101327284B (en) * | 2007-06-18 | 2011-11-09 | 徐乃江 | Anticoagulant medicine made from Chinese medicine |
| CN102125662B (en) * | 2010-07-19 | 2012-08-08 | 李振国 | Compound traditional Chinese medicine for treating apoplexia and preparation method and application thereof |
| CN102895534B (en) * | 2012-10-22 | 2014-04-02 | 于纪魁 | Chinese medicinal capsule for treating ischemic stroke |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1185961A (en) * | 1996-12-26 | 1998-07-01 | 郭贵江 | Capsule for apoplexy |
| CN1235047A (en) * | 1999-04-20 | 1999-11-17 | 丁志忠 | Prescription of Tongshuanjiangyawan as hypotensor and thrombolytic medicine and preparing method thereof |
| CN1309992A (en) * | 2000-11-02 | 2001-08-29 | 郑国芃 | Apoplexy curing decoction |
-
2004
- 2004-10-15 CN CNB2004100839728A patent/CN1296087C/en not_active Expired - Lifetime
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1185961A (en) * | 1996-12-26 | 1998-07-01 | 郭贵江 | Capsule for apoplexy |
| CN1235047A (en) * | 1999-04-20 | 1999-11-17 | 丁志忠 | Prescription of Tongshuanjiangyawan as hypotensor and thrombolytic medicine and preparing method thereof |
| CN1309992A (en) * | 2000-11-02 | 2001-08-29 | 郑国芃 | Apoplexy curing decoction |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1602949A (en) | 2005-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1248702C (en) | Traditional Chinese medicine preparation for treating coronary heart disease angina pectoris and preparation method thereof | |
| CN101195016A (en) | Medicine for treating apoplexy and its preparing process | |
| CN1296087C (en) | Compound capsule for treating apoplexy involving the meridians of wind phlegm stasis blockage syndrome type and preparation process thereof | |
| CN102357134B (en) | Medicine for preventing and treating Alzheimer disease and cerebral thrombosis and preparation method thereof | |
| CN1883533A (en) | Pharmaceutical composition for treating apoplexy and preparation method thereof | |
| CN1067901C (en) | Drug for curing migraine and its preparing method | |
| CN101890062A (en) | Application of nard pine and its extract in the preparation of medicine for treating gastric ulcer | |
| CN1745795A (en) | Medicine for preventing and treating coronary heart disease and preparation method thereof | |
| CN1857607A (en) | Chinese medicine preparation for treating cardiac and cerebral vascular diseases and its preparing process | |
| CN1593489A (en) | Traditional Chinese Medicinal formulation for treating coronary heart disease and preparation method thereof | |
| CN1272026C (en) | Medicinal composition for treating cardiocerebral vasculr disease and its preparing method | |
| CN1186067C (en) | Medicine for curing acute injury of muscle and tendon and its preparation method | |
| CN1618445A (en) | A kind of medicine for treating cardiovascular disease and preparation method thereof | |
| CN1245197C (en) | Chinese medicine preparation for treating coronary heart disease and viral myocarditis | |
| CN1679697A (en) | Chinese medicine preparation for treating cardio vascular disease and containing notoginseng, pericarpium trichosanthis and leech, for treating cardio-cerebral blood vessel diseases and its preparing | |
| CN1142786C (en) | Medicine for treating coronary heart disease | |
| CN100396279C (en) | A kind of traditional Chinese medicine preparation for treating arrhythmia and preparation method thereof | |
| CN117018144B (en) | A Chinese medicine composition and its pharmaceutical use | |
| CN112206279B (en) | Traditional Chinese medicine composition for treating ventricular arrhythmia and preparation method and application thereof | |
| CN1293971A (en) | Medicine for treating apoplexy and its preparing process | |
| CN1333044A (en) | Wasting-thirst hypoglycemic preparation | |
| CN100339093C (en) | Compound medicine for treating coronary heart disease and angina pectoris and its preparing process | |
| CN1220504C (en) | Medicine for treating coronary disease and preparing method thereof | |
| CN1634241A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1277559C (en) | Medicine for treating rheumatism and its preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20070124 |